Cerbios-Pharma gains new director of commercial business development

Will help firm to grow and strengthen HPAPI services

Stefano Console has joined Cerbios-Pharma as director of commercial business development.

Prior to joining Cerbios, Console was business and financial director at Micro-Macinazione.

Cerbios-Pharma is a Swiss firm based in Lugano specialising in the development and manufacturing of chemical and biological APIs.

APIs made by Cerbios cover small molecules (Chemical Division), large molecules and probiotics (Biological Division).

The Chemical Division specialises not only in reduced folates, but also in the manufacturing of High Potency Active Ingredients (HPAIs) with long-term experience in Vitamin D derivatives requiring sophisticated production units with high containment levels.

The Biological Division specializes in the research, development and production of Probiotics as active pharmaceutical ingredients, pharmaceutical finished products and feed additives.

You may also like

Manufacturing

Cerbios-Pharma opens HPAI plant

Investment in Barbengo, Switzerland, is part of an expansion strategy started in 1996
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Ingredients

Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing

The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies
Ingredients

Therapeutic: vimseltinib for tenosynovial giant cell tumour

Tenosynovial giant cell tumour (TGCT) is a rare, non-malignant tumour that results from a translocation in the colony stimulating factor 1 (CSF1) gene
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Ingredients

Logical Biological expands its raw pharma material development and supply capabilities with new lab

The raw material supplier can now better serve in vitro diagnostic (IVD) manufacturers, as it has a significantly larger operational capacity
Ingredients

Biosynth inaugurates its Biological Technology site in Suzhou, China

The new site will serve the Chinese domestic market, providing raw materials for vaccines and pharmaceuticals, while dealing regional distribution and handling
Subscribe now